Yoseph Shaaltiel - Protalix BioTherapeutics Insider

Protalix BioTherapeutics Inc -- USA Stock  

USD 0.781  0.009  1.14%

Founder and Executive VP of RandD

Dr. Yoseph Shaaltiel, Ph.D., is Executive Vice President Research Development of the company. Dr. Shaaltiel founded Protalix Ltd. in 1993 and has served as our Executive Vice President, Research and Development since December 2006. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey. He has coauthored over 40 articles and abstracts on plant biochemistry and holds several patents
Age: 62  Founder Since 2016  Ph.D    
(972) 4 988 9488  www.protalix.com
Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.

Management Efficiency

The company has Return on Asset of (29.5) % which means that on every $100 spent on asset it lost $29.5. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (30.1) % meaning that it generated no profit with money invested by stockholders.
The company has 57.88 M in debt with debt to equity (D/E) ratio of 6.63 . This implies that the company may be unable to create cash to meet all of its financial commitments. Protalix BioTherapeutics Inc has Current Ratio of 2.51 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Entity Summary

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics Inc (PLX) is traded on American Stock Exchange in USA. It is located in ISRAEL and employs 223 people. Protalix BioTherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Suggestion Now
   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  Next  Launch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Protalix BioTherapeutics Inc to your portfolio

Top Management

Protalix BioTherapeutics Leadership Team
Roger Kornberg, Director, Ph.D
Yoseph Shaaltiel, Founder, Ph.D
Yossi Maimon, President, MBA
Shlomo Yanai, Chairman, Ph.D
Amos BarShalev, Director, MBA
Tzvi Palash, COO, MBA
Aharon Schwartz, Director, Ph.D
Marcy Nanus, Executive
Zeev Bronfeld, Chairman
Moshe Manor, CEO, MBA
Einat Almon, SVP, Ph.D
Yodfat Buchris, Director, MBA

Stock Performance

Protalix BioTherapeutics Performance Indicators